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Abstract
Background: Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity.
In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7
non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-
response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in
comparison with a placebo. The aim of this presentation is to give more details about the dose-
response effects of short-chain fructo-oligosaccharides (scFOS).
Methods: Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly
divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a
placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar
consumption, and tolerance was evaluated using a daily chart.
Results (m ± SEM): Bifidobacteria counts increase was higher in scFOS than in placebo group for
all doses tested [2.5 g/d (from 9.15 ± 0.59 to 9.39 ± 0.70; P = 0.02); 5 g/d (from 10.21 ± 0.21 to
10.67 ± 0.22; P = 0.03); 7.5 g/d (from 9.28 ± 0.49 to 9.85 ± 0.35;P = 0.01); 10 g/d (from 9.00 ± 0.81
to 10.18 ± 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal
bifidobacteria counts was observed at d15 (r2 = 0.307, P < 0.001). Total anaerobes increased at the
dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria
or pH in any group. The frequency of digestive symptoms was not different between scFOS at any
of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at
doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal
pain did not differ from the placebo at any of the doses tested.
Conclusion: This study showed that scFOS is bifidogenic and well tolerated at doses ranging from
2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers.
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Short chain fructo-oligosaccharides (scFOS) are a mixture
of oligosaccharides consisting of glucose linked to fruc-
tose units; links between fructose units are β-(1,2) [1].
They are produced commercially from sucrose using an
enzymatic process. ScFOS are poorly digested in the
human small intestine but are fermented in the colon by
the resident microflora [2].
In light of the recent interest in "prebiotics", defined as "a
non-digestible food ingredient that beneficially affects the
host by selectively stimulating the growth and/or the
activity of one or a limited number of bacterial species in
the colon" [3], it has been shown in humans that addition
to the diet of short-chain fructo-oligosaccharides (scFOS)
at doses of from 4 to 12.5 g/d leads to an increase in faecal
bifidobacteria counts [4,5]. Such bifidobacteria-promot-
ing dietary interventions can be perceived as beneficial,
since bifidobacteria are a saccharolytic genus and could
contribute to the same type of protection that breast-feed-
ing provides against gut infections [6], while also playing
a role in the prevention of colorectal carcinogenesis [4,5].
In a recent study comprising 200 healthy volunteers, we
determined the bifidogenic properties of 7 non-digestible
carbohydrates administered at a dose of 10 g/d in the
human diet : Four non-digestible carbohydrates were
found to be statistically different from placebo, i.e. bifi-
dogenic, at 10 g/d: scFOS, soybean-oligosaccharides,
galacto-oligosaccharides and type III resistant starch; we
therefore performed a dose-response relationship analysis
of these 4 substrates at doses ranging from 2.5 to 10 g/d
and compared them to a placebo [7]. The effects of the 7-
day treatment period were found to be significantly differ-
ent among the 4 non-digestible carbohydrates (P =
0.009). A trend was found for the doses tested (P= 0.06)
suggesting that the relationship between dose and bifido-
bacteria count could be different among the 4 non-digest-
ible carbohydrates, and that among them, a dose-
response effect could be present. Since we previously dem-
onstrated a dose-response relationship between scFOS
and bifidobacteria at higher doses [5], we considered it of
interest to investigate a possible dose-response relation-
ship between scFOS and bifidobacteria at lower doses.
Methods
Subjects
Forty healthy volunteers [18 males, 22 females, age 29 ±
1.3 (mean ± SEM)] were included. Exclusion criteria were:
history of gastrointestinal disease except for appendec-
tomy; antibiotics or laxatives taken during the two
months before the study; use of other medication during
the investigation period. Subjects gave written informed
consent to take part in the study, which was performed in
accordance with local legislation, the ICH guidelines and
the principles laid down in the current version of the Dec-
laration of Helsinki, and was approved by an Ethics Com-
mittee (the "Comité Consultatif pour la Protection des
Personnes se prêtant à la Recherche Biomédicale" of Saint
Louis Hospital, Paris, France).
The scFOS tested was Actilight™ [Beghin Meiji, Paris,
France, comprising 44% 1-kestose (GF2), 46% nystose
(GF3) and 10% 1F-β-fructofuranosyl nystose (GF4)]; the
placebo was 50% sucrose – 50% fully digestible waxy
maize-derived maltodextrins (DE6.5) (Cerestar, Vil-
voorde, Belgium).
Experimental design
To evaluate possible dose-response effects on the intesti-
nal microflora, 40 volunteers were randomized to 5
groups of 8 subjects and they ingested scFOS at a daily
dose of 2.5, 5.0, 7.5 or 10 g/d from d8 to d14 or the pla-
cebo in two oral doses after lunch and dinner. All subjects
consumed their usual daily diet from the pre-inclusion
day (d0) to the end of the study (d15). They were
instructed to exclude from their diet fermented dairy
products containing viable bifidobacteria and to limit
consumption of foods containing high levels of non-
digestible oligosaccharides such as onion, asparagus,
wheat, rye, triticale and Jerusalem artichoke.
Digestive symptoms
Gastrointestinal side effects were evaluated using a daily
chart in which symptoms (excess flatus, borborygmi,
bloating, abdominal pain) were graded from 0 (no symp-
toms) to 3 (severe symptoms). The frequency and consist-
ency of stools were also noted by the volunteers and
diarrhoea was defined as one or more watery stools, or
more than 3 stools per day.
Stool collection
Stools were recovered twice, on the morning of d8 before
the start of scFOS consumption, and on the morning of
d15, i.e. after 7d of scFOS consumption (d8 to d14). Sam-
ples were collected in plastic containers rendered anaero-
bic (Anaerocult A; Merck, Darmstadt, Germany),
immediately stored at 4°C, transferred to the laboratory
and analyzed. The procedure from stool emission to bac-
teriological analysis lasted less than 1 hour.
Bacterial counts and pH
Faecal samples (1 g) were introduced in the first pre-
weighed tube of the dilution series and thoroughly mixed
and then further ten-fold dilutions were made in a
reduced diluent (cysteinated 1/4 strength Ringer diluent).
0.1 ml of each dilution was plated in different selective
media to outnumber several bacterial genera: total anaer-
obic counts (Wilkins-Chalgren agar), Bifidobacterium
(Beerens' medium), Lactobacillus (MRS agar), BacteroidesPage 2 of 6
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were duplicated for the first two media. Plates of the first
three media were incubated anaerobically for 5 to 7 days,
MRS agar for 48 hours under atmosphere enriched in CO2
and McConkey agar aerobically for 48 hours. Colony
counts were obtained and expressed as a log of the colony-
forming units (CFU) per gram of fresh faeces. At the same
time, the fresh stool pH was measured by pH meter
(Bioblock, Illkirch, France).
Data analysis
The descriptive statistics used the mean and standard error
of the mean (m ± sem).
Efficacy analysis: The comparisons between each dose of
scFOS versus placebo were performed on variations of
bacteria counts (differences after-before treatment for bifi-
dobacteria and other bacteria) using the unpaired t-test.
Since the difference between days 8 to 15 compared with
placebo was the reference, p-values are not reported.
A dose-response relationship was therefore sought using
the linear regression model.
Tolerance analysis: a global analysis of the observed fre-
quencies was performed for the 5 groups during the treat-
ment period and for each symptom using a chi2 test.
Symptom intensity was recorded every day as follows: 0:
no symptoms; 1: mild symptoms; 2: moderate symptoms;
3: severe symptoms, resulting in a daily score.
All daily scores were added for each symptom 1) before
the treatment period from d1 to d8 (a.m.) and 2) during
Table 1: Faecal bifidobacteria and total anaerobe counts (m ± SEM, log cfu/g) in 40 healthy volunteers assigned to a 7-d consumption of 
short-chain fructo-oligosaccharides (scFOS) at a dose from 2.5 to 10 g/d or a placebo
scFOS dose (g/d) Total anaerobes Bifidobacteria
d8* d15* ∆d15-d8 P** d8* d15* ∆ d15-d8 P**
0 (placebo) 12.59 ± 0.17 12.54 ± 0.12 - 0.05 ± 0.16 *** 10.06 ± 0.29 9.57 ± 0.21 - 0.49 ± 0.23 ***
2.5 12.32 ± 0.21 12.55 ± 0.14 + 0.22 ± 0.19 0.29 9.15 ± 0.59 9.39 ± 0.70 + 0.24 ± 0.16 0.02
5.0 12.48 ± 0.18 12.66 ± 0.14 + 0.17 ± 0.28 0.51 10.21 ± 0.21 10.67 ± 0.22 + 0.46 ± 0.31 0.03
7.5 12.45 ± 0.16 12.55 ± 0.13 + 0.09 ± 0.06 0.42 9.28 ± 0.49 9.85 ± 0.35 + 0.57 ± 0.25 0.01
10 11.65 ± 0.37 12.68 ± 0.14 + 1.04 ± 0.41 0.03 9.00 ± 0.81 10.18 ± 0.60 + 1.18 ± 0.42 0.003
*days 1–8 was a run-in period during which no treatment occurred, but subjects excluded from their diet fermented dairy products containing 
viable bifidobacteria and limited consumption of food products containing high level of non-digestible oligosaccharides.
** Statistical analyses were performed versus placebo, on the difference d15-d8, using an unpaired t-test
*** As the difference days 15-8 with placebo was the reference, p-values are not reported.
Table 2: Bacterial counts and pH (m ± SEM, log cfu/g) in 40 healthy volunteers assigned to a 7-d consumption of short-chain fructo-
oligosaccharides (scFOS) at a dose from 2.5 to 10 g/d or a placebo
scFOS 
dose (g/d)
Lactobacillus Bacteroides Enterobacteria pH
d8* d15* P** d8* d15* P** d8* d15* P** d8* d15* P**
0 (placebo) 5.21 ± 0.36 5.18 ± 0.41 *** 8.76 ± 0.45 8.53 ± 0.32 *** 6.93 ± 0.29 7.07 ± 0.37 *** 6.94 ± 0.13 6.91 ± 0.11 ***
2.5 4.66 ± 0.48 5.14 ± 0.60 NS 8.93 ± 0.28 9.08 ± 0.17 NS 6.93 ± 0.26 7.28 ± 0.33 NS 6.68 ± 0.18 6.75 ± 0.14 NS
5.0 5.34 ± 0.66 5.99 ± 0.67 NS 8.87 ± 0.18 9.09 ± 0.28 NS 7.34 ± 0.33 7.81 ± 0.32 NS 6.48 ± 0.15 6.52 ± 0.11 NS
7.5 5.37 ± 0.40 5.97 ± 0.39 NS 8.74 ± 0.25 8.61 ± 0.29 NS 6.30 ± 0.29 6. 78 ± 0.26 NS 6.66 ± 0.13 6. 78 ± 0.13 NS
10 5.40 ± 0.41 5.73 ± 0.83 NS 8.51 ± 0.41 9. 39 ± 0.26 NS 6.28 ± 0.40 6.58 ± 0.32 NS 7.05 ± 0.21 7.20 ± 0.25 NS
*days 1–8 was a run-in period during which no treatment occurred, but subjects excluded from their diet fermented dairy products containing viable 
bifidobacteria and limited consumption of food products containing high level of non-digestible oligosaccharides.
** Statistical analyses were performed versus placebo, on the difference d15-d8, using an unpaired t-test
*** As the difference days 15-8 with placebo was the reference, p-values are not reported.Page 3 of 6
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test the differences (doses versus placebo) on variation in
total score (differences During-Before treatment). The
same procedure was used (ANOVA, Fisher's test).
Results
Faecal bacterial counts and pH
Bifidobacteria counts increased in the scFOS groups at the
doses of 2.5, 5, 7.5 and 10 g/d. Total anaerobes increased
at the dose of 10 g/d (Table 1). No significant differences
were found for Bacteroides, Lactobacillus, enterobacteria
and pH in any group (Table 2).
Dose-effect of scFOS on bifidobacteria concentrations
Bifidobacteria counts did not differ significantly among
the groups at d1. A significant correlation between the
dose of ingested scFOS and faecal bifidobacteria counts
was observed on the d15 – d8 difference (r2= 0.307, P <
0.001) (Figure 1).
Digestive tolerance
Digestive symptom frequency, as assessed by cumulative
daily scores, did not differ between placebo and scFOS at
all doses tested (Table 3). Bloating was significantly more
intense during scFOS ingestion at doses of 2.5 and 5 g/d,
but not at doses of 7.5 and 10 g/d (Table 4). Excess flatus,
borborygmi and abdominal pains were no different from
placebo at all doses tested (Table 4). No diarrhoea was
reported by any subjects.
Discussion
This placebo-controlled dose-response study shows that 7
days of ingestion of scFOS at a dose of 2.5 to 10 g/d, which
was well tolerated, led to a significant increase in faecal
bifidobacteria in healthy volunteers. This is the first study
to demonstrate the bifidogenic effect of sc-FOS with such
a low dose (2.5 g/d). Moreover, it must be stressed that the
increase in bifidobacteria counts was correlated with the
dose of ingested scFOS. We previously reported such an
effect in healthy volunteers in another dose-response rela-
tionship study. However, the optimal and well-tolerated
dose of scFOS leading to a significant increase in faecal
bifidobacteria under usual diet was 10 g/d. These differ-
ences are probably due to the relatively small size of each
sample, which decreased the power of the study. The
increase in total anaerobes observed at the dose of 10 g/d
is probably due to the high stimulation of colonic micro-
flora induced by prebiotics [8,9]. The faecal bifidobacteria
and anaerobe levels observed in this study were similar to
those found in previous studies [3,5] in healthy volun-
teers on scFOS.
ScFOS has been studied extensively and its bifidogenic
effects demonstrated in well-controlled human trials [3-
5,8]. However, Roberfroid et al. concluded from a compi-
lation work that in a large population, there seems to be
no dose-response effect of these non-digestible carbohy-
drates on bifidobacteria for daily intake doses between 4
and 40 g/d [10]. Here, we found a linear dose-response
relationship from 2.5 to 10 g/d, suggesting a dose-effect
relationship. Such a relationship has been previously
found in a study with scFOS, in which the range of doses
was wider, from 5 to 20 g/d [8], and in another trial using
a mixture of galacto- and fructooligosaccharides as sup-
plementation of term infant formula [11]. It was not
found with other substrates such as galacto-oligosaccha-
rides alone, resistant starch or soybean oligosaccharides
[7].
We did not find any significant reduction in any other
genus. There is little published data in humans available
in the literature for comparison. Contradictory results
have been reported in this field; while Gibson et al. [3]
showed a significant reduction in Bacteroides using 15 g/
d oligofructose, Rao [9] found an increase in Bacteroides
using oligofructose at dose of 5 g/d. Moreover using oli-
gofructose at 8 g/d, 2 authors did not find any effect on
Bacteroide [7,12]. The reasons for these discrepancies are
unclear.
A decrease in colonic pH could reduce the risk of develop-
ing colonic cancer, since an inverse correlation between
stool pH and colon cancer risk was observed [13,14].
Slight acidification of faecal contents during scFOS inges-
tion was observed in animals [15] and in humans [12]. In
our previous studies, faecal pH did not change during
ingestion of scFOS [5,8]. However, as the faecal pH is the
net sum of the degree of short-chain fatty acid absorption
and bicarbonate secretion during passage through the
Correlation between the dose of ingested scFOS and the fae-cal bifidobacteria counts on the d15 – d8 differenceFigure 1
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under physiological conditions [16,17].
Symptoms relating to gas production in the gut are widely
reported in human prebiotic feeding studies but neverthe-
less remain very mild at the recommended intake levels
[18,19]. Compared to placebo, we did not find any signif-
icant digestive intolerance symptoms except minor bloat-
ing with scFOS. Similarly, no dose-response relationship
for digestive symptoms was observed. In a threshold study
to evaluate symptomatic response to varying levels of
scFOS ingested regularly by 14 healthy volunteers, exces-
sive flatus and borborygmi were reported by about 10% of
volunteers at 10 g/d of scFOS, and excessive flatus, borbo-
rygmi and bloating were recorded for about 20–30% of
volunteers at 20 g/d [20]. In another study in which 10
volunteers ingested 15 g/d FOS for 12 days, gaseous symp-
toms such as abdominal cramps, excess flatus and bloat-
ing were all significantly more severe in subjects ingesting
the FOS than in control subjects ingesting sucrose (P <
0.05) [21]. However, with the exception of flatulence,
these symptoms, if present, were usually mild, and did not
increase (or decrease) during the course of the 12-day
period. In our previous study comprising 10 healthy vol-
unteers who ingested 12.5 g/d of scFOS for 12 days, only
bloating was found to be significantly more frequent dur-
ing the scFOS ingestion period than during placebo inges-
tion (P < 0.05), but this was very mild and present in only
5/10 volunteers [5]. From all these results, it appears that
the most common symptoms noted during scFOS admin-
istration are excess flatus and/or bloating, but only a
minority of subjects experiences them and they are usually
very mild.
Table 3: Observed frequencies for digestive symptoms (n and % of column totals), during the treatment period in 40 healthy 
volunteers assigned to a 7-d consumption of short-chain fructo-oligosaccharides (scFOS) at a dose from 2.5 to 10 g/d or a placebo
scFOS dose (g/d) Excess flatus Bloating Borborygmi Abdominal pain
n % n % n % n %
0 (placebo) 6/8 75 5/8 62.5 4/8 50 3/8 37.5
2.5 7/8 87.5 6/8 75 5/8 62.5 4/8 50
5.0 6/8 75 4/8 50 5/8 62.5 3/8 37.5
7.5 7/8 87.5 4/8 50 3/8 37.5 5/8 62.5
10 7/8 87.5 6/8 75 4/8 50 5/8 62.5
Table 4: Intensity of digestive symptoms (scores) in 40 healthy volunteers assigned to a 7-d consumption of short-chain fructo-
oligosaccharides (scFOS) at a dose from 2.5 to 10 g/d or a placebo
scFOS 
dose (g/d)
Excess flatus Bloating Borborygmi Abdominal pain
d1-d8* d8-d15* P** d1-d8* d8-d15* P** d1-d8* d8-d15* P** d1-d8* d8-d15* P**
0 (placebo) 4.12 ± 1.35 4.12 ± 1.45 *** 3.87 ± 1.80 2.62 ± 0.92 *** 3.25 ± 1.80 2.75 ± 1.47 *** 1.50 ± 1.00 0.50 ± 0.26 ***
2.5 1.75 ± 0.45 3.62 ± 1.28 NS 1.50 ± 0.42 3.12 ± 1.28 0.03 1.37 ± 0.49 300 ± 1.36 NS 1.12 ± 0.61 1.12 ± 0.61 NS
5.0 3.00 ± 1.08 5.25 ± 1.71 NS 1.75 ± 0.97 3.37 ± 1.76 0.03 1.75 ± 0.92 2.87 ± 1.42 NS 0.87 ± 0.51 0.87 ± 0.51 NS
7.5 3.50 ± 0.86 3.50 ± 0.68 NS 1.75 ± 1.03 1.50 ± 0.62 NS 1.75 ± 0.64 0.62 ± 0.32 NS 2.12 ± 0.87 2.12 ± 0.87 NS
10 3.37 ± 1.16 4.75 ± 1.03 NS 2.25 ± 1.06 2.62 ± 1.16 NS 1.50 ± 0.75 1.62 ± 0.86 NS 2.12 ± 0.81 2.12 ± 0.81 NS
*days 1–8 was a run-in period during which no treatment occurred, but subjects excluded from their diet fermented dairy products containing 
viable bifidobacteria and limited consumption of food products containing high level of non-digestible oligosaccharides.
** Statistical analyses were performed versus placebo, on the difference d15-d8, using Fisher's Test
*** As the difference days 15-8 with placebo was the reference, p-values are not reported. Symptom intensity was noted every day using a 4-grade 
scale 0: no symptom; 1: mild symptoms; 2: moderate symptoms; 3: severe symptoms. Cumulative daily scores were calculated for each period [d1, 
d8 a.m.], [d8 p.m., d15] and are reported in the present table as m ± sem. Severity of symptoms and cumulative daily scores can be related via the 
following scale: 0: no symptom; 1–7: mild symptoms; 8–14: moderate symptoms; 15–21: severe symptoms.Page 5 of 6
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This study confirmed that scFOS is bifidogenic and well
tolerated in healthy volunteers. A bifidogenic effect
appeared for the first time at 2.5 g/d of scFOS, and a dose-
response relationship was demonstrated from 2.5 to 10 g/
d.
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